Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors

Current Medicinal Chemistry

Volumn 18, Issue 19, 2011, Pages 2885-2892

  Filippi, I ^a   Naldini, A ^a   Carraro, F ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bcr Abl; Chronic myeloid leukemia; Hypoxia; Src; Tyrosine kinase inhibitors; VEGF

Indexed keywords

ABELSON KINASE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; ENVIRONMENTAL FACTOR; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HYPOXIA; MICROENVIRONMENT; REMISSION; SRC HOMOLOGY DOMAIN; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SRC-FAMILY KINASES; TUMOR MICROENVIRONMENT;

EID: 79959964494     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796150540     Document Type: Article

References (138)

1. Schwarz, G. Ueber Desensibilisierung gegen rontgenund radiumstrahlen. Munchener Medizinische Wochenschrift, 1909, 24, 1-2.
2. Churchill-Davidson, I.; Sanger, C.; Thomlinson, R. H. High-pressure oxygen and radiotherapy. Lancet, 1955, 268(6874), 1091-1095.
3. Vaupel, P.; Kelleher, D. K.; Hockel, M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol., 2001, 28(2 Suppl 8), 29-35. (Pubitemid 32522235)
4. Vaupel, P.; Harrison, L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist., 2004, 9 Suppl 5, 4-9. (Pubitemid 39658340)
5. Naldini, A.; Filippi, I.; Ardinghi, C.; Silini, A.; Giavazzi, R.; Carraro, F. Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. Eur. J. Cancer, 2009, 45(3), 454-460.
6. Vaupel, P. The role of hypoxia-induced factors in tumor progression. Oncologist., 2004, 9 Suppl 5, 10-17. (Pubitemid 39658341)
7. Czekay, R. P.; Aertgeerts, K.; Curriden, S. A.; Loskutoff, D. J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol., 2003, 160(5), 781-791. (Pubitemid 36298272)
8. Semenza, G. L.; Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol., 1992, 12(12), 5447-5454.
9. Wang, G. L.; Semenza, G. L. Purification and characterization of hypoxiainducible factor 1. J. Biol. Chem., 1995, 270(3), 1230-1237.
10. Nordsmark, M.; Bentzen, S. M.; Rudat, V.; Brizel, D.; Lartigau, E.; Stadler, P.; Becker, A.; Adam, M.; Molls, M.; Dunst, J.; Terris, D. J.; Overgaard, J. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol., 2005, 77(1), 18-24. (Pubitemid 41503384)
11. Fyles, A.; Milosevic, M.; Hedley, D.; Pintilie, M.; Levin, W.; Manchul, L.; Hill, R. P. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol., 2002, 20(3), 680-687. (Pubitemid 34111374)
12. Ruan, K.; Song, G.; Ouyang, G. Role of hypoxia in the hallmarks of human cancer. J. Cell Biochem., 2009, 107(6), 1053-1062.
13. Bache, M.; Kappler, M.; Said, H. M.; Staab, A.; Vordermark, D. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr. Med Chem., 2008, 15(4), 322-338. (Pubitemid 351266939)
14. Laderoute, K.; Wardman, P.; Rauth, A. M. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide (SR 4233). Biochem. Pharmacol., 1988, 37(8), 1487-1495. (Pubitemid 18093342)
15. Reck, M.; von, P. J.; Nimmermann, C.; Groth, G.; Gatzemeier, U. [Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)]. Pneumologie, 2004, 58(12), 845-849. (Pubitemid 40069757)
16. Braun, R. D.; Lanzen, J. L.; Snyder, S. A.; Dewhirst, M. W. Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. Am. J. Physiol Heart Circ. Physiol, 2001, 280(6), H2533-H2544.
17. Whalen, W. J.; Ganfield, R.; Nair, P. Effects of breathing O 2 or O 2 +CO 2 and of the injection of neurohumors on the PO 2 of cat cerebral cortex. Stroke, 1970, 1(3), 194-200.
18. Nwaigwe, C. I.; Roche, M. A.; Grinberg, O.; Dunn, J. F. Effect of hyperventilation on brain tissue oxygenation and cerebrovenous PO2 in rats. Brain Res., 2000, 868(1), 150-156. (Pubitemid 30332356)
19. Hemphill, J. C., III; Morabito, D.; Farrant, M.; Manley, G. T. Brain tissue oxygen monitoring in intracerebral hemorrhage. Neurocrit. Care, 2005, 3(3), 260-270. (Pubitemid 43004824)
20. Buerk, D. G.; Shonat, R. D.; Riva, C. E.; Cranstoun, S. D. O2 gradients and countercurrent exchange in the cat vitreous humor near retinal arterioles and venules. Microvasc. Res., 1993, 45(2), 134-148.
21. Tondevold, E.; Eriksen, J.; Jansen, E. Observations on long bone medullary pressures in relation to arterial PO2, PCO2 and pH in the anaesthetized dog. Acta Orthop. Scand., 1979, 50(6 Pt 1), 645-651. (Pubitemid 10162506)
22. Takubo, K.; Goda, N.; Yamada, W.; Iriuchishima, H.; Ikeda, E.; Kubota, Y.; Shima, H.; Johnson, R. S.; Hirao, A.; Suematsu, M.; Suda, T. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell, 2010, 7(3), 391-402.
23. Ivanovic, Z.; Dello, S. P.; Trimoreau, F.; Faucher, J. L.; Praloran, V. Primitive human HPCs are better maintained and expanded in vitro at 1 percent oxygen than at 20 percent. Transfusion, 2000, 40(12), 1482-1488. (Pubitemid 32049053)
24. Ivanovic, Z.; Belloc, F.; Faucher, J. L.; Cipolleschi, M. G.; Praloran, V.; Dello, S. P. Hypoxia maintains and interleukin-3 reduces the pre-colonyforming cell potential of dividing CD34 (+) murine bone marrow cells. Exp. Hematol., 2002, 30(1), 67-73. (Pubitemid 34061853)
25. Huang, Y.; Du, K. M.; Xue, Z. H.; Yan, H.; Li, D.; Liu, W.; Chen, Z.; Zhao, Q.; Tong, J. H.; Zhu, Y. S.; Chen, G. Q. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia, 2003, 17(11), 2065-2073. (Pubitemid 37441189)
26. Li, B. Z.; Zhuang, W. Z.; Chen, P.; Fu, J. X. [Effects of RNA interference targeting hypoxia-inducible factor-1alpha (HIF-1alpha) on chemosensitivity of leukemia K562 cells towards homoharringtonine]. Ai. Zheng., 2008, 27(7), 723-728.
27. Wang, F.; Chen, B. A.; Cheng, J.; Xu, W. L.; Wang, X. M.; Ding, J. H.; Gao, C.; Sun, Y. Y.; Wang, J.; Zhao, G.; Bao, W.; Song, H. H.; Gao, F.; Zhang, W.; Xia, G. H.; Pei, X. P.; Wu, W. W.; Yin, L.; Shan, X. Y. [Effects of hypoxia-inducible factor inhibitor on expression of HIF-1alpha and VEGF and induction of apoptosis in leukemic cell lines]. Zhongguo Shi Yan. Xue. Ye. Xue. Za Zhi., 2010, 18(1), 74-78.
28. Nie, Y. M.; Dai, B. T. [Enhancement effects of hypoxia on invasion and metastasis of K562 cells]. Zhongguo Dang. Dai Er. Ke. Za Zhi., 2009, 11(7), 566-570.
29. Di Giacomo, V.; Rapino, M.; Miscia, S.; Di, G. C.; Cataldi, A. Dual role of HIF-1alpha in delivering a survival or death signal in hypoxia exposed human K562 erythroleukemia cells. Cell Biol. Int, 2009, 33(1), 49-56.
30. Krebs, E. G.; Fischer, E. H. Phosphorylase activity of skeletal muscle extracts. J. Biol. Chem., 1955, 216(1), 113-120.
31. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298(5600), 1912-1934. (Pubitemid 35425239)
32. Roskoski, R., Jr. RAF protein-serine/threonine kinases: structure and regulation. Biochem. Biophys. Res. Commun., 2010, 399(3), 313-317.
33. Dengjel, J.; Kratchmarova, I.; Blagoev, B. Receptor tyrosine kinase signaling: a view from quantitative proteomics. Mol. Biosyst., 2009, 5(10), 1112-1121.
34. Bae, J. H.; Lew, E. D.; Yuzawa, S.; Tome, F.; Lax, I.; Schlessinger, J. The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell, 2009, 138(3), 514-524.
35. O'Dwyer, M. E.; Druker, B. J. Chronic myelogenous leukaemia-new therapeutic principles. J. Intern. Med., 2001, 250(1), 3-9. (Pubitemid 34208932)
36. Faderl, S.; Talpaz, M.; Estrov, Z.; Kantarjian, H. M. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med., 1999, 131(3), 207-219. (Pubitemid 29365004)
37. Konopka, J. B.; Watanabe, S. M.; Witte, O. N. An alteration of the human cabl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell, 1984, 37(3), 1035-1042. (Pubitemid 15139294)
38. Lugo, T. G.; Pendergast, A. M.; Muller, A. J.; Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 1990, 247(4946), 1079-1082.
39. Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta, D. J.; Reese, S. F.; Ford, J. M.; Capdeville, R.; Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 2001, 344(14), 1038-1042. (Pubitemid 32267973)
40. Lewis, J. M.; Baskaran, R.; Taagepera, S.; Schwartz, M. A.; Wang, J. Y. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc. Natl. Acad. Sci. U. S. A, 1996, 93(26), 15174-15179.
41. McWhirter, J. R.; Wang, J. Y. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell Biol., 1991, 11(3), 1553-1565. (Pubitemid 21895513)
42. Bedi, A.; Zehnbauer, B. A.; Barber, J. P.; Sharkis, S. J.; Jones, R. J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood, 1994, 83(8), 2038-2044. (Pubitemid 24112713)
43. Gesbert, F.; Griffin, J. D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood, 2000, 96(6), 2269-2276.
44. Horita, M.; Andreu, E. J.; Benito, A.; Arbona, C.; Sanz, C.; Benet, I.; Prosper, F.; Fernandez-Luna, J. L. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med, 2000, 191(6), 977-984.
45. Verfaillie, C. M.; Hurley, R.; Zhao, R. C.; Prosper, F.; Delforge, M.; Bhatia, R. Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? J. Lab Clin. Med, 1997, 129(6), 584-591. (Pubitemid 27288660)
46. Mandanas, R. A.; Leibowitz, D. S.; Gharehbaghi, K.; Tauchi, T.; Burgess, G. S.; Miyazawa, K.; Jayaram, H. N.; Boswell, H. S. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood, 1993, 82(6), 1838-1847. (Pubitemid 23278775)
47. Puil, L.; Liu, J.; Gish, G.; Mbamalu, G.; Bowtell, D.; Pelicci, P. G.; Arlinghaus, R.; Pawson, T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J., 1994, 13(4), 764-773. (Pubitemid 24057507)
48. Cortez, D.; Reuther, G.; Pendergast, A. M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene, 1997, 15(19), 2333-2342. (Pubitemid 27496983)
49. Raitano, A. B.; Halpern, J. R.; Hambuch, T. M.; Sawyers, C. L. The Bcr-Abl leukemia oncogene activates Jun. kinase and requires Jun. for transformation. Proc. Natl. Acad. Sci. U. S. A, 1995, 92(25), 11746-11750. (Pubitemid 26014190)
50. Carlesso, N.; Frank, D. A.; Griffin, J. D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med, 1996, 183(3), 811-820. (Pubitemid 26113953)
51. Shuai, K.; Halpern, J.; ten, H. J.; Rao, X.; Sawyers, C. L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene, 1996, 13(2), 247-254. (Pubitemid 26334856)
52. Skorski, T.; Kanakaraj, P.; Nieborowska-Skorska, M.; Ratajczak, M. Z.; Wen, S. C.; Zon, G.; Gewirtz, A. M.; Perussia, B.; Calabretta, B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood, 1995, 86(2), 726-736.
53. Danhauser-Riedl, S.; Warmuth, M.; Druker, B. J.; Emmerich, B.; Hallek, M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res., 1996, 56(15), 3589-3596. (Pubitemid 26251657)
54. Wang, L. H.; Duesberg, P. H.; Kawai, S.; Hanafusa, H. Location of envelope-specific and sarcoma-specific oligonucleotides on RNA of Schmidt-Ruppin Rous sarcoma virus. Proc. Natl. Acad. Sci. U. S. A, 1976, 73(2), 447-451.
55. Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol., 1997, 13, 513-609. (Pubitemid 28034534)
56. Frame, M. C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta, 2002, 1602(2), 114-130. (Pubitemid 34521791)
57. Li, S. Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. Expert. Opin. Ther. Targets., 2005, 9(2), 329-341. (Pubitemid 40613872)
58. Lynch, S. A.; Brugge, J. S.; Fromowitz, F.; Glantz, L.; Wang, P.; Caruso, R.; Viola, M. V. Increased expression of the src proto-oncogene in hairy cell leukemia and a subgroup of B-cell lymphomas. Leukemia, 1993, 7(9), 1416-1422. (Pubitemid 23291084)
59. Yamaguchi, M.; Tanaka, T.; Waki, M.; Kitanaka, A.; Kamano, H.; Kubota, Y.; Ohnishi, H.; Takahara, J.; Irino, S. Antisense src expression inhibits tyrosine phosphorylation of Shc and its association with Grb2 and Sos which leads to MAP kinase activation in U937 human leukemia cells. Leukemia, 1997, 11(4), 497-503. (Pubitemid 27173936)
60. Hu, Y.; Liu, Y.; Pelletier, S.; Buchdunger, E.; Warmuth, M.; Fabbro, D.; Hallek, M.; Van Etten, R. A.; Li, S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet., 2004, 36(5), 453-461. (Pubitemid 38620028)
61. Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res., 2000, 60(2), 203-212. (Pubitemid 30070735)
62. Veikkola, T.; Alitalo, K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol., 1999, 9(3), 211-220. (Pubitemid 29273837)
63. Xie, B.; Tam, N. N.; Tsao, S. W.; Wong, Y. C. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br. J. Cancer, 1999, 81(8), 1335-1343.
64. Abu-Jawdeh, G. M.; Faix, J. D.; Niloff, J.; Tognazzi, K.; Manseau, E.; Dvorak, H. F.; Brown, L. F. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest, 1996, 74(6), 1105-1115. (Pubitemid 26184421)
65. Takanami, I.; Tanaka, F.; Hashizume, T.; Kodaira, S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res., 1997, 17(4 A), 2811-2814. (Pubitemid 27352692)
66. Fiedler, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D. K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 1997, 89(6), 1870-1875. (Pubitemid 27132100)
67. Ratajczak, M. Z.; Ratajczak, J.; Machalinski, B.; Majka, M.; Marlicz, W.; Carter, A.; Pietrzkowski, Z.; Gewirtz, A. M. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth. Br. J. Haematol., 1998, 103(4), 969-979. (Pubitemid 29012632)
68. Bellamy, W. T.; Richter, L.; Frutiger, Y.; Grogan, T. M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res., 1999, 59(3), 728-733. (Pubitemid 29076074)
69. Verstovsek, S.; Lunin, S.; Kantarjian, H.; Manshouri, T.; Faderl, S.; Cortes, J.; Giles, F.; Albitar, M. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk. Res., 2003, 27(7), 661-669. (Pubitemid 36398103)
70. Aguayo, A.; Kantarjian, H.; Manshouri, T.; Gidel, C.; Estey, E.; Thomas, D.; Koller, C.; Estrov, Z.; O'Brien, S.; Keating, M.; Freireich, E.; Albitar, M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000, 96(6), 2240-2245.
71. Bellamy, W. T.; Richter, L.; Sirjani, D.; Roxas, C.; Glinsmann-Gibson, B.; Frutiger, Y.; Grogan, T. M.; List, A. F. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood, 2001, 97(5), 1427-1434. (Pubitemid 32183769)
72. Aguayo, A.; Estey, E.; Kantarjian, H.; Mansouri, T.; Gidel, C.; Keating, M.; Giles, F.; Estrov, Z.; Barlogie, B.; Albitar, M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 1999, 94(11), 3717-3721.
73. Lundberg, L. G.; Lerner, R.; Sundelin, P.; Rogers, R.; Folkman, J.; Palmblad, J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol., 2000, 157(1), 15-19. (Pubitemid 30641719)
74. Mayerhofer, M.; Valent, P.; Sperr, W. R.; Griffin, J. D.; Sillaber, C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood, 2002, 100(10), 3767-3775. (Pubitemid 35303950)
75. Yaish, P.; Gazit, A.; Gilon, C.; Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science, 1988, 242(4880), 933-935. (Pubitemid 19015255)
76. Gazit, A.; Yaish, P.; Gilon, C.; Levitzki, A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med Chem., 1989, 32(10), 2344-2352. (Pubitemid 19245898)
77. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B. J.; Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56(1), 100-104.
78. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U. S. A, 1995, 92(7), 2558-2562.
79. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med, 1996, 2(5), 561-566.
80. Deininger, M. W.; Goldman, J. M.; Lydon, N.; Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 1997, 90(9), 3691-3698. (Pubitemid 27473440)
81. Druker BJ; Sawyers CL; Talpaz M. Phase I trial of a specific abl tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients. Proc ASCO 18:24a. 1999. Ref Type: Generic
82. Druker, B. J.; Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest, 2000, 105(1), 3-7. (Pubitemid 30036380)
83. +CML). Blood 96:470a (abstract). 2000. Ref Type: Generic
84. + chronic myeloid leukemia in accelerated phase. Blood 96:469a (abstract). 2000. Ref Type: Generic
85. + chronic myeloid leukemia in myeloid blast crisis. Blood 96:503a (abstract). 2000. Ref Type: Generic
86. + acute leukemias. Blood 96:828a (abstract). 2000. Ref Type: Generic
87. O'Brien, S. G.; Guilhot, F.; Larson, R. A.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J. J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J. L.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J. M.; Kantarjian, H.; Taylor, K.; Verhoef, G.; Bolton, A. E.; Capdeville, R.; Druker, B. J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med, 2003, 348(11), 994-1004. (Pubitemid 36302244)
88. Habeck, M. FDA licences imatinib mesylate for CML. Lancet Oncol., 2002, 3(1), 6. (Pubitemid 34121132)
89. Silver, R. T.; Woolf, S. H.; Hehlmann, R.; Appelbaum, F. R.; Anderson, J.; Bennett, C.; Goldman, J. M.; Guilhot, F.; Kantarjian, H. M.; Lichtin, A. E.; Talpaz, M.; Tura, S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 1999, 94(5), 1517-1536. (Pubitemid 29411301)
90. Chen, P.; Zong, L.; Zhao, W.; Shi, L. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. World J. Gastroenterol., 2010, 16(33), 4227-4232.
91. Besmer, P.; Murphy, J. E.; George, P. C.; Qiu, F. H.; Bergold, P. J.; Lederman, L.; Snyder, H. W., Jr.; Brodeur, D.; Zuckerman, E. E.; Hardy, W. D. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature, 1986, 320(6061), 415-421. (Pubitemid 16097805)
92. Joensuu, H.; Roberts, P. J.; Sarlomo-Rikala, M.; Andersson, L. C.; Tervahartiala, P.; Tuveson, D.; Silberman, S.; Capdeville, R.; Dimitrijevic, S.; Druker, B.; Demetri, G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med, 2001, 344(14), 1052-1056. (Pubitemid 32267975)
93. Dagher, R.; Cohen, M.; Williams, G.; Rothmann, M.; Gobburu, J.; Robbie, G.; Rahman, A.; Chen, G.; Staten, A.; Griebel, D.; Pazdur, R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res., 2002, 8(10), 3034-3038. (Pubitemid 35155011)
94. Croom, K. F.; Perry, C. M. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs, 2003, 63(5), 513-522. (Pubitemid 36337730)
95. Branford, S.; Rudzki, Z.; Walsh, S.; Parkinson, I.; Grigg, A.; Szer, J.; Taylor, K.; Herrmann, R.; Seymour, J. F.; Arthur, C.; Joske, D.; Lynch, K.; Hughes, T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the AT P phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 2003, 102(1), 276-283. (Pubitemid 36759665)
96. Hochhaus, A.; Kreil, S.; Corbin, A. S.; La, R. P.; Muller, M. C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 2002, 16(11), 2190-2196. (Pubitemid 35331833)
97. Mahon, F. X.; Deininger, M. W.; Schultheis, B.; Chabrol, J.; Reiffers, J.; Goldman, J. M.; Melo, J. V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 2000, 96(3), 1070-1079. (Pubitemid 30616875)
98. Dai, Y.; Rahmani, M.; Corey, S. J.; Dent, P.; Grant, S. A Bcr/Ablindependent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem., 2004, 279(33), 34227-34239. (Pubitemid 39318046)
99. Burger, H.; van, T. H.; Brok, M.; Wiemer, E. A.; de Bruijn, E. A.; Guetens, G.; de, B. G.; Sparreboom, A.; Verweij, J.; Nooter, K. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol. Ther., 2005, 4(7), 747-752. (Pubitemid 41351174)
100. Cortes, J.; O'Brien, S.; Kantarjian, H. Discontinuation of imatinib therapy after achieving a molecular response. Blood, 2004, 104(7), 2204-2205. (Pubitemid 39297882)
101. Golemovic, M.; Verstovsek, S.; Giles, F.; Cortes, J.; Manshouri, T.; Manley, P. W.; Mestan, J.; Dugan, M.; Alland, L.; Griffin, J. D.; Arlinghaus, R. B.; Sun, T.; Kantarjian, H.; Beran, M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res., 2005, 11(13), 4941-4947. (Pubitemid 41557215)
102. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7(2), 129-141. (Pubitemid 40248339)
103. Wilson, M. B.; Schreiner, S. J.; Choi, H. J.; Kamens, J.; Smithgall, T. E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene, 2002, 21(53), 8075-8088. (Pubitemid 35454411)
104. Hu, Y.; Swerdlow, S.; Duffy, T. M.; Weinmann, R.; Lee, F. Y.; Li, S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. U. S. A, 2006, 103(45), 16870-16875. (Pubitemid 44737345)
105. Li, S. Src kinase signaling in leukaemia. Int J. Biochem. Cell Biol., 2007, 39(7-8), 1483-1488. (Pubitemid 47031028)
106. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 2002, 62(15), 4236-4243. (Pubitemid 34827278)
107. Carraro, F.; Naldini, A.; Pucci, A.; Locatelli, G. A.; Maga, G.; Schenone, S.; Bruno, O.; Ranise, A.; Bondavalli, F.; Brullo, C.; Fossa, P.; Menozzi, G.; Mosti, L.; Modugno, M.; Tintori, C.; Manetti, F.; Botta, M. Pyrazolo[3, 4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J. Med. Chem., 2006, 49(5), 1549-1561. (Pubitemid 43376502)
108. Dreassi, E.; Zizzari, A. T.; Mori, M.; Filippi, I.; Belfiore, A.; Naldini, A.; Carraro, F.; Santucci, A.; Schenone, S.; Botta, M. 2-Hydroxypropyl-bcyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3, 4-d]pyrimidines Src-Abl dual inhibitors. Eur. J. Med. Chem., in press.
109. Manetti, F.; Pucci, A.; Magnani, M.; Locatelli, G. A.; Brullo, C.; Naldini, A.; Schenone, S.; Maga, G.; Carraro, F.; Botta, M. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3, 4-d]pyrimidines in human leukemia cells. ChemMedChem., 2007, 2(3), 343-353.
110. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl) - piperazin-1-yl)-2- methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med Chem., 2004, 47(27), 6658-6661. (Pubitemid 40053752)
111. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305(5682), 399-401. (Pubitemid 38938156)
112. Mahon, F. X.; Hayette, S.; Lagarde, V.; Belloc, F.; Turcq, B.; Nicolini, F.; Belanger, C.; Manley, P. W.; Leroy, C.; Etienne, G.; Roche, S.; Pasquet, J. M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res., 2008, 68(23), 9809-9816.
113. Kimura, S.; Naito, H.; Segawa, H.; Kuroda, J.; Yuasa, T.; Sato, K.; Yokota, A.; Kamitsuji, Y.; Kawata, E.; Ashihara, E.; Nakaya, Y.; Naruoka, H.; Wakayama, T.; Nasu, K.; Asaki, T.; Niwa, T.; Hirabayashi, K.; Maekawa, T. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 2005, 106(12), 3948-3954. (Pubitemid 41739036)
114. Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M. E.; Paquette, R. L.; Kuriyan, J.; Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2002, 2(2), 117-125. (Pubitemid 41039112)
115. Puttini, M.; Coluccia, A. M.; Boschelli, F.; Cleris, L.; Marchesi, E.; Donella-Deana, A.; Ahmed, S.; Redaelli, S.; Piazza, R.; Magistroni, V.; Andreoni, F.; Scapozza, L.; Formelli, F.; Gambacorti-Passerini, C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res., 2006, 66(23), 11314-11322. (Pubitemid 46009962)
116. Schenone, S.; Brullo, C.; Musumeci, F.; Botta, M. Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert. Opin. Investig. Drugs, 2010, 19(8), 931-945.
117. Bradeen, H. A.; Eide, C. A.; O'Hare, T.; Johnson, K. J.; Willis, S. G.; Lee, F. Y.; Druker, B. J.; Deininger, M. W. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood, 2006, 108(7), 2332-2338. (Pubitemid 44497517)
118. Palandri, F.; Castagnetti, F.; Iacobucci, I.; Martinelli, G.; Amabile, M.; Gugliotta, G.; Poerio, A.; Testoni, N.; Breccia, M.; Bocchia, M.; Crugnola, M.; Rege-Cambrin, G.; Martino, B.; Pierri, I.; Radaelli, F.; Specchia, G.; Pane, F.; Saglio, G.; Rosti, G.; Baccarani, M. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica, 2010, 95(8), 1415-1419.
119. Burchert, A.; Muller, M. C.; Kostrewa, P.; Erben, P.; Bostel, T.; Liebler, S.; Hehlmann, R.; Neubauer, A.; Hochhaus, A. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol., 2010, 28(8), 1429-1435.
120. Ebos, J. M.; Tran, J.; Master, Z.; Dumont, D.; Melo, J. V.; Buchdunger, E.; Kerbel, R. S. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol. Cancer Res., 2002, 1(2), 89-95. (Pubitemid 36306767)
121. Shin, H. W.; Cho, C. H.; Kim, T. Y.; Park, J. W. Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells. Biochem. Biophys. Res. Commun., 2010, 398(2), 205-211.
122. Manetti, F.; Brullo, C.; Magnani, M.; Mosci, F.; Chelli, B.; Crespan, E.; Schenone, S.; Naldini, A.; Bruno, O.; Trincavelli, M. L.; Maga, G.; Carraro, F.; Martini, C.; Bondavalli, F.; Botta, M. Structure-based optimization of pyrazolo[3, 4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J. Med Chem., 2008, 51(5), 1252-1259. (Pubitemid 351480387)
123. Zhao, F.; Mancuso, A.; Bui, T. V.; Tong, X.; Gruber, J. J.; Swider, C. R.; Sanchez, P. V.; Lum, J. J.; Sayed, N.; Melo, J. V.; Perl, A. E.; Carroll, M.; Tuttle, S. W.; Thompson, C. B. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene, 2010, 29(20), 2962-2972.
124. Takeuchi, M.; Kimura, S.; Kuroda, J.; Ashihara, E.; Kawatani, M.; Osada, H.; Umezawa, K.; Yasui, E.; Imoto, M.; Tsuruo, T.; Yokota, A.; Tanaka, R.; Nagao, R.; Nakahata, T.; Fujiyama, Y.; Maekawa, T. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death. Differ., 2010, 17(7), 1211-1220.
125. Quintas-Cardama, A.; Kantarjian, H.; Garcia-Manero, G.; O'Brien, S.; Faderl, S.; Estrov, Z.; Giles, F.; Murgo, A.; Ladie, N.; Verstovsek, S.; Cortes, J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 2007, 109(2), 248-255. (Pubitemid 46106239)
126. Dehm, S. M.; Bonham, K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem. Cell Biol., 2004, 82(2), 263-274. (Pubitemid 38680178)
127. Lluis, J. M.; Buricchi, F.; Chiarugi, P.; Morales, A.; Fernandez-Checa, J. C. Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. Cancer Res., 2007, 67(15), 7368-7377. (Pubitemid 47206567)
128. Pham, N. A.; Magalhaes, J. M.; Do, T.; Schwock, J.; Dhani, N.; Cao, P. J.; Hill, R. P.; Hedley, D. W. Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. Int J. Cancer, 2009, 124(2), 280-286.
129. Eliceiri, B. P.; Paul, R.; Schwartzberg, P. L.; Hood, J. D.; Leng, J.; Cheresh, D. A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell, 1999, 4(6), 915-924. (Pubitemid 30054898)
130. Mukhopadhyay, D.; Tsiokas, L.; Zhou, X. M.; Foster, D.; Brugge, J. S.; Sukhatme, V. P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature, 1995, 375(6532), 577-581.
131. Zhang, Q.; Wang, D.; Kundumani-Sridharan, V.; Gadiparthi, L.; Johnson, D. A.; Tigyi, G. J.; Rao, G. N. PLD1-dependent PKCgamma activation downstream to Src is essential for the development of pathologic retinal neovascularization. Blood, 2010, 116(8), 1377-1385.
132. Jiang, B. H.; Agani, F.; Passaniti, A.; Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res., 1997, 57(23), 5328-5335. (Pubitemid 27516371)
133. Takacova, M.; Holotnakova, T.; Barathova, M.; Pastorekova, S.; Kopacek, J.; Pastorek, J. Src induces expression of carbonic anhydrase IX via hypoxiainducible factor 1. Oncol. Rep., 2010, 23(3), 869-874.
134. Perez-Atayde, A. R.; Sallan, S. E.; Tedrow, U.; Connors, S.; Allred, E.; Folkman, J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol., 1997, 150(3), 815-821. (Pubitemid 27106153)
135. Padro, T.; Ruiz, S.; Bieker, R.; Burger, H.; Steins, M.; Kienast, J.; Buchner, T.; Berdel, W. E.; Mesters, R. M. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 2000, 95(8), 2637-2644. (Pubitemid 30210544)
136. Hussong, J. W.; Rodgers, G. M.; Shami, P. J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 2000, 95(1), 309-313. (Pubitemid 30017257)
137. Verstovsek, S.; Kantarjian, H.; Manshouri, T.; Cortes, J.; Giles, F. J.; Rogers, A.; Albitar, M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood, 2002, 99(6), 2265-2267. (Pubitemid 34525520)
138. Giatromanolaki, A.; Bai, M.; Margaritis, D.; Bourantas, K. L.; Koukourakis, M. I.; Sivridis, E.; Gatter, K. C. Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res., 2010, 30(7), 2831-2836.